Skip to main content
. 2012 Oct 9;7(10):e45826. doi: 10.1371/journal.pone.0045826

Figure 2. Long-term outcome of patients depending on NGAL expression and intensity in months.

Figure 2

(A) DFS in all patients by NGAL expression neg. vs. pos. (B) DFS in all patients by NGAL intensity 0–1 vs. 2–3. (C) DFS in HR positive patients by NGAL expression neg. vs. pos. (D) DFS in HR positive patients by NGAL intensity 0–1 vs. 2–3. (E) DFS in patients without pCR by NGAL expression neg. vs. pos. (F) OS in patients without pCR by NGAL intensity 0–1 vs. 2–3. NGAL: neutrophil gelatinase-associated lipocalin. DFS: disease-free survival. OS: overall survival. HR: hormone.